Baseline demographic and disease characteristics
Age, y | |
| Mean ± SD | 63.5 ± 14.1 |
| Median | 66.0 |
| Range | 21.0-82.0 |
| Younger than 50 (%) | 2 (9.5) |
| At least 50 (%) | 19 (90.5) |
| Sex, no. (%) | |
| Male | 9 (46.9%) |
| Female | 12 (57.1%) |
| ECOG performance status, no. (%) | |
| 0 | 6 (28.6) |
| 1 | 8 (38.1) |
| 2 | 7 (33.3) |
| Duration of disease, mo/d | |
| Mean ± SD | 15.9 ± 24.94/479.5 ± 748.4 |
| Median | 9.2/278.0 |
| Range | 0.2-112.2/5.0-3380.0 |
| Disease characteristics, no. (%) | |
| Not eligible for CT | 3 (14) |
| Refractory | 5 (24) |
| Relapsed | 13 (62) |
| Interval between last dose of induction/consolidation CT to start of imatinib | |
| Median, d | 158 |
| Range, d | 21-616 |
| Previous CT cycles, no. (%) | |
| None | 3 (14) |
| 1-2 | 10 (48) |
| At least 3 | 8 (38) |
| Previous allogeneic PBSC-T, no. (%) | 4 (19) |
| PB blast count, × 109/L (median/range) | 0.87 (0-59.9) |
| BM blast cell infiltration (%) | 50.5 (2-90) |
| WBC, × 109/L (median/range) | 4.4 (1.0-76.9) |
| Hb, mg/dL (median/range) | 9.1 (6.6-12.5) |
| PLT, × 109/L (median/range) | 46 (10-2400) |
Age, y | |
| Mean ± SD | 63.5 ± 14.1 |
| Median | 66.0 |
| Range | 21.0-82.0 |
| Younger than 50 (%) | 2 (9.5) |
| At least 50 (%) | 19 (90.5) |
| Sex, no. (%) | |
| Male | 9 (46.9%) |
| Female | 12 (57.1%) |
| ECOG performance status, no. (%) | |
| 0 | 6 (28.6) |
| 1 | 8 (38.1) |
| 2 | 7 (33.3) |
| Duration of disease, mo/d | |
| Mean ± SD | 15.9 ± 24.94/479.5 ± 748.4 |
| Median | 9.2/278.0 |
| Range | 0.2-112.2/5.0-3380.0 |
| Disease characteristics, no. (%) | |
| Not eligible for CT | 3 (14) |
| Refractory | 5 (24) |
| Relapsed | 13 (62) |
| Interval between last dose of induction/consolidation CT to start of imatinib | |
| Median, d | 158 |
| Range, d | 21-616 |
| Previous CT cycles, no. (%) | |
| None | 3 (14) |
| 1-2 | 10 (48) |
| At least 3 | 8 (38) |
| Previous allogeneic PBSC-T, no. (%) | 4 (19) |
| PB blast count, × 109/L (median/range) | 0.87 (0-59.9) |
| BM blast cell infiltration (%) | 50.5 (2-90) |
| WBC, × 109/L (median/range) | 4.4 (1.0-76.9) |
| Hb, mg/dL (median/range) | 9.1 (6.6-12.5) |
| PLT, × 109/L (median/range) | 46 (10-2400) |
PBSC-T indicates peripheral blood stem cell transplantation; PB, peripheral blood; BM, bone marrow; WBC, white blood count; Hb, hemoglobin; PLT, platelets; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group.